Sunovion seeks FDA nod for sublingual film to treat Parkinson’s disease

Sunovion Pharmaceuticals submitted a new drug application to the FDA this week for its apomorphine sublingual film designed to treat motor fluctuations experienced by people with Parkinson’s disease.

The Marlborough, Mass.-based company is testing the film as a therapy for Parkinson’s patients experiencing “off” episodes – when symptoms that are otherwise controlled by medications resurface. As many as 60% of Parkinson’s patients have these kinds of episodes, according to the company.

“Off episodes, which may be characterized by symptoms such as tremor, stiffness or slow movement, may disrupt the ability to perform everyday activities and may be burdensome for patients, families and caregivers,” Dr. Antony Loebel, EVP & CMO, said in prepared remarks.

Sunovion reported that the therapy performed well compared to a placebo in a pivotal Phase III trial and that the drug’s effect lasted for 90 minutes following initial administration. The film, which has fast-track status with the FDA, was also generally well tolerated by patients in the trial, according to the company.

Sunovion’s drug is gearing up to compete with Acorda Therapeutics‘ (NSDQ:ACOR) inhaled Parkinson’s therapy, Inbrija, which is also under review by the U.S. regulatory agency.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

DeviceTalks Boston 2018 is Bigger and Better than ever! Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it all began. DeviceTalks offers three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry. Early Registration is now open.